Introduction
Acute myeloid leukemia (AML) is a group of heterogeneous diseases characterized by an uncontrolled proliferation of hematopoietic progenitor cells that have lost their normal capacity to differentiate into mature blood cells. The clinical outcomes of AML are variable but are typically poor (except for acute promyelocytic leukemia), with a 30% median overall survival. In addition to age and white blood cell count, cytogenetic and molecular genetic investigations have become a major part of the routine diagnostic approach for AML. Pretreatment chromosomal abnormalities are a major prognostic marker evaluated in clinical decision-making and risk adaptive treatment strategy. 1, 2 However, despite continuous improvements in methods, approximately 50% of AML patients have a normal or non-informative karyotype and are considered to have an intermediate prognosis.
Global gene expression studies have indicated that molecular profiling could provide useful data about the variety of AMLs. 3 Specific molecular signatures are associated with cytogenetic abnormalities and can identify particular prognostic subclasses among normal karyotype AML. 4, 5 Nevertheless, there is expanding evidence that a large range of gene products are not necessarily driven by altered transcript levels. Because of mRNA alternative splicing, allelic variations and post-translational modifications, the genome can produce well over an estimated million protein species, compared with the estimated 25 000 open reading frames that it contains. Proteomic studies thus represent a very promising method to complement mRNA-based measurements and obtain significant insights into the molecular signature of complex biological systems. 6 In the past few years, mass spectrometry (MS) has emerged as an efficient complementary method to 2D electrophoresis, considerably increasing the relevance and accuracy of proteomics. 7 Numerous technical advances have made MS-based methods powerful strategies for identifying proteins in complex mixtures. Tandem-MS (that is, nanoLC MS/MS) has been used to characterize the proteome of several organisms, organelles and other multi-protein complexes. Progress in genome sequencing and enhanced bioinformatics tools have allowed proteomics to become a promising analytical method in cancer research. Protein expression patterns may identify not only proteins with potentially pivotal roles in oncogenesis but also accurate biomarkers of a patient's outcome. 8, 9 In the field of hematology, evidence that leukemia FAB (French American British) subtypes, 10 cytogenetic risk groups 11 and hematopoietic stem cell-like fractions 12 are associated with specific proteomes has already been published. The interest and importance of proteomics in the research of prognostic markers was revealed for AML, 13, 14 clinical behavior predictions in adult acute lymphoblastic leukemia 15 and therapy-related proteome variations. 16 Finally, functional proteomic profiling confirmed that specific protein expression patterns correlate with outcome and prognosis, thus providing new molecular classifications useful for predicting the risk of AML patients at diagnosis. 17 In this context, we developed a surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-based protein profile of leukemic cells associated with tandem MS (MALDI-TOF/TOF and nanoLC MS/MS) to identify new, specific biomarkers of high-risk AML that are present at the time of diagnosis.
Patients and methods

Patient population and sample processing
Two independent cohorts of patients were retrospectively selected from two different university hospitals belonging to the 'Groupe d'Etude Ouest-Est des Leucémies aigues' (GOELAMS). All of the patients were newly diagnosed with AML, and a sample of bone marrow or peripheral blood mononuclear cells was collected and frozen before any treatment after obtaining informed consent. In both cohorts, patients represented M0-M7 subtypes, excluding acute promyelocytic leukemia and therapy-related AML. The patients were treated according to the current chemotherapy protocols in place at the time of sampling with anthracycline and high-dose ara-C-based regimens. Cytogenetic classifications were available for all of the patients. We designated favorable patients as those patients harboring karyotypic abnormalities associated with a good prognosis, intermediate patients as those with an indeterminate prognosis and unfavorable patients as those with a bad prognosis. 18 The first cohort of patients included 37 patients ( . They all have a normal karyotype. At the time of analysis, seven patients had died, whereas ten were in sustained complete remission. Demographic and clinical characteristics of the two patient sets are described in Table 1 . It could be noticed that both cohorts consisted of younger patients compared with the average leukemic population. This point needs to be considered when analyzing survival and cure fractions.
Bone marrow mononuclear cells were separated by FicollHypaque gradient separation, allowing less than 5% residual contamination by polymorphonuclear cells. The percentage of leukemic cells was evaluated by the microscopic count of a May-Grunwald-Giemsa-stained cytospin slide. All of the selected specimens had more than 50% blast cells before enrichment.
SELDI-TOF protein chip array
Protein profiling was performed using a system based on SELDI-TOF (Ciphergen; Biorad, Hercules, CA, USA) MS. SELDI-TOF chips fractionate lysates based on the affinity surface binding of proteins, improving the resolution of discrete peaks by significantly reducing sample complexity. SELDI-TOF also allows for the simultaneous analysis of a large number of patients within the same MS run, such that protein profiles can be studied based on clustering.
After thawing, cell pellets were resuspended with lysis buffer containing 7 M urea, 2 M thio-urea, 4% 3-((3-cholamidopropyl)-dimethylammonio)-1-propanesulfonate (CHAPS), 1% dithiothreitol and a cocktail of proteolysis inhibitors. Extracted proteins were separated by centrifugation at 12 000 Â g for 20 min. The protein concentration was determined using the Bradford protein assay. Whole-cell lysate aliquots were stored at À80 1C until the time of protein analysis. To avoid interassay variability, all samples from each set were prepared (thawed, protein-extracted and assayed for concentration) at the same time during a single process by a single technician. A total of 15 mg of protein from whole-cell extracts from each sample was analyzed on ProteinChip array (Biorad, Marnes la Coquette, France) surfaces involving chromatographic stationary phase chemistry, anion exchange (Q10) and cation exchange (CM10). Protein and peptide masses were detected directly from the stationary phase using the same laser desorption/ionization MS protocol for each spot and each array. A liquid-handling robot (Biomek 2000; Beckman Coulter, Villepinte, France) and an automated autoloader were used to supply the ProteinChip arrays for sample preparation. The mass/charge (m/z) spectra of the bound proteins were generated in a Ciphergen Protein Biology System II (Ciphergen Biosystems). Data were collected by averaging 65 laser shots per spot. Two laser intensities were used for each spot.
Analysis of SELDI-TOF mass spectra Spectra were obtained using two different acquisition protocols for low (2.5-14 kDa) and high (14-400 kDa) molecular mass proteins, respectively. An external mass calibration was performed with ProteinChip All-in-One Protein Standard II (Bio-Rad Laboratories, Hercules, CA, USA) before the run to assure a mass accuracy of nearly 0.1%. Qualified mass peaks (signal-to-noise ratio 45) were auto-detected and normalized to the total ion current in the range of 3-150 kDa after both the baseline was subtracted and the noise was reduced. Each sample was thereby characterized by a pattern of several peaks, each one corresponding to a protein or a peptide that was characterized by a mass/charge ratio (m/z) and its intensity. Each patient's protein profile was defined by the pattern of qualifying peaks. Interpatient comparisons of the median and mean peak intensities were based on a P-value determined by nonparametric intersample comparisons with the Mann-Whitney U-test, which tests the null hypothesis that the medians of the peak intensities of the groups are equal. A P-value o0.05 was accepted as statistically significant. Classification of patients according to their protein profiles was performed using an integrated pair of programs, Cluster and TreeView (http://rana.lbl.gov/Eisensoftware.htm). To evaluate the clinical interest of a protein profile-based classification, we performed an unsupervised hierarchical clustering of samples. Unsupervised analysis classifies patients into clusters harboring similar protein profiles independent of their clinical characteristics. The disease-free survival and overall survival (OS) between the proteomic clusters were estimated using Kaplan-Meier log rank survival analysis.
To identify prognostic biomarkers, a classification tree was developed with biomarker pattern software (Ciphergen Biosystems). The classification tree split data into two nodes, using one rule at a time in the form of a question (for example, is the patient alive?). Each identified peak becomes a variable in the classification process and is evaluated for its discriminative value for the question being answered. Peaks are thereby hierarchically classified in a classification tree according to their discriminative value. Splitting is continued until terminal nodes are reached and further splitting gives no gain in data classification.
Protein purification and identification
The 10 800-Da marker was purified using a CM Hyper-DF spin column (Biorad), using the fixing and eluting conditions predetermined on protein chips. The elution fraction was run on a precast Novex Nupage Bis-Tris gel (4-12% acrylamide gradient) purchased from Invitrogen (Cergy Pontoise, France). The gel was fixed in 30% ethanol/7.5% acetic acid before staining with Biosafe Coomassie blue (Bio-Rad). Bands near the 10.8-kDa marker were excised and prepared for in-gel trypsin digestion. Subsequently, 2 ml of the digestion mixture was analyzed on a normal phase ProteinChip array (H50). Masses for all the detected peptides were matched with the Mascot and Profound search engines.
To identify the proteins, peptide mixtures were analyzed using a MALDI-TOF/TOF 4800 proteomics analyzer mass spectrometer (Applied Biosystems, Courtaboeuf, France) in positive reflector ion mode. Samples were directly spotted onto a MALDI plate using a-cyano-4-hydroxy-cinnamic acid as the matrix in a 1:1 ratio. MS spectra from m/z 700-3500 were acquired using 1500 laser shots; the 10 peaks from each MS spectrum with the highest intensity above an S/N threshold of 100 were selected for MS/MS analysis. Each sample was analyzed three times in order to increase the number of peptides identified and thus increase the final protein coverage. MS and MS/MS data were analyzed using the Global Proteome Server Explorer software V3.6 (Applied Biosystems) and proteins were identified using the Mascot V2.0 (Matrix Science, IMGT, Paris, France) search engine. Database searches were performed using the SwissProt databank. Some samples were also subjected to nanoLC-MS/MS (nano liquid chromatography-MS/MS) analysis. For this analysis, the dried extracted peptides were resuspended in 4% acetonitrile and 0.2% trifluoroacetic acid and analyzed by online nanoLC-MS/MS (Ultimate 3000, Dionex and LTQ-Orbitrap, Thermo Fischer Scientific). MS and MS/MS data were acquired using Xcalibur (Thermo Fischer Scientific, Strasbourd, France) and processed automatically using Mascot Daemon software (Matrix Science). Searches against the SwissProt/TrEMBL(decoy) database were performed using Mascot 2.1 (local license). Peptide modifications that were allowed during the search included: acetyl (N-ter), dioxidation (M), oxidation (M) and trioxidation (C). Proteins identified with a minimum of two peptides and a score higher than the query threshold (P-value o0.01) were automatically validated using IRMa (Interprétation des résultats Mascott). For each identified protein, the exponentially modified protein abundance index and spectral count values were calculated.
Western blot
A total of 14 mg of protein per patient (11 mg for granulocyte cytosols and 1 mg for recombinant proteins) was loaded per lane on a 12.5% SDS-PAGE gel. After electrophoresis, proteins were transferred to a polyvinylidene fluoride membrane in transfer buffer (25 mM Tris, 192 mM glycine, 0.01% sodium dodecyl sulfate, 20% methanol, pH 8.6) for 2 h 30 min. The membranes were blocked by incubating for 30 min in phosphate-buffered saline containing 5% non-fat milk at room temperature and were then incubated for 1 h 30 min at 4 1C with goat polyclonal antihuman-MRP8 primary antibodies (TEBU Santa Cruz, Le Perroy en Yvelines, France). After washing in phosphatebuffered saline containing 0.1% Tween, the membranes were incubated for 30 min with donkey anti-goat horseradish peroxidase-conjugated secondary antibodies (TEBU Santa Cruz SC-2020). After washing in phosphate-buffered saline containing Tween, the specific reactions were visualized using an ECL Western blot detection system (Amersham, GE Healthcare, Munich, Germany).
Results
Proteomic profiling: clinical correlation
SELDI-TOF analysis of Q10 and CM10 ProteinChips qualified 164 peaks from 3 to 175 kDa that were expressed in all patients. Unsupervised clustering of patients based on the relative peaks' intensities from Q10 array identified two distinct clusters (1 and 2) of 19 and 18 patients, respectively ( Figure 1 ). Clusters 1 and 2 included 6 and 16 patients who had died, respectively. Of all patients who died, 72.7% (16/22) were partitioned in cluster 2, whereas 86.6% (13/15) of surviving patients were in cluster 1. The two clusters were not significantly different in sex ratio, age or FAB subtypes (Figure 2a) . Survival analysis showed a highly significant difference in OS (P ¼ 0.001) between the two clusters ( Figure 2b ). Event-free survival also varied significantly between clusters (60 vs 0% for groups 1 and 2, respectively (P ¼ 0.0004)). Based on this first analysis, we used the following nomenclature in our study: patients from proteomic cluster 1 were designated as belonging to the good proteomic prognosis; patients from proteomic cluster 2 were designated as belonging to the bad proteomic prognosis.
Because these preliminary results strongly suggested that a proteomic classification system could be of clinical interest, we compared its predictive value with current prognostic factors. In our study, cytogenetic classification and being over 60 years old were independent prognostic factors for OS and disease-free survival. White blood cell counts over 30 g/l could not be identified as an independent predictor, probably because of the small group size. In this context, we focused on relationships between proteomic and cytogenetic classifications. Cytogenetic subgroups were randomly scattered among the two proteomic clusters. Normal karyotypes were equally distributed in clusters 1 (n ¼ 13) and 2 (n ¼ 11). Similarly, patients from both favorable and unfavorable cytogenetic groups were randomly distributed among the two clusters (Figure 2a) . A Cox regression model showed that proteomic profiling-based predictions were independent (Po0.02) of cytogenetic classification, suggesting that the protein signature could refine cytogenetic subgroups.
To further evaluate complementarities between proteomic and cytogenetic classification, patients were split into four classes (A-D) based on the proteomic and cytogenetic subgroups to which they belonged (Figure 3a) . Because cytogenetic group 1 only included two patients, we did not include them in this analysis. This classification allowed a new stratification that highly correlated with the outcome (P ¼ 0.0001) (Figure 3b) . Patients from the intermediate cytogenetic group could be separated into two classes (A and B) with significantly different OS (P ¼ 0.002) and event-free survival (P ¼ 0.0004). Patients from class A displayed a probability of survival similar to the favorable cytogenetic group, whereas class B patients' survival was close to the unfavorable cytogenetic group. Similarly, among patients with high-risk cytogenetic profiles, proteomic profiling identified two groups of patients: a subset with a survival time lower than 20 months (class D) and a subset (class C ¼ low cytogenetic prognosis but good proteomic prognosis) with a probability of survival similar to the intermediate cytogenetic group.
Prognostic value of a 10 800-Da peak Our second aim was to identify a protein marker that significantly correlated with survival. We therefore performed a comparative statistical analysis of the intensity of the 60 peaks obtained by MS analysis on Q10 array. This analysis resulted in 30 peaks with a significant difference (Po0.05) between the two clusters. Among these candidate markers, hierarchical classification using Biomarker Patterns Software (Ciphergen Biosystems) selected a 10 800-Da peak as the most significant split marker between survival and death (P ¼ 0.009). The median intensity (measured at 1800 nJ on Q10 array) of the 10 800-Da peak was 24.7 ± 26.14 (0.5-397) in living patients compared with 158.05±31.05 (3.6-395.6) in dead patients (P ¼ 0.01) (Figure 4a) Figure 1 Unsupervised clustering analysis of AML patients. Unsupervised hierarchical clustering of the first cohort of patients (n ¼ 37) according to the relative levels of protein or peptide masses isolated using Q10 array. Data are shown in a matrix format, where each row represents a protein or a peptide and each column represents a patient. Expression levels of each protein in a single sample are relative to their median abundance across all samples and are depicted according to a color scale. Red and green boxes indicate expression levels above and below the median, respectively. The magnitude of deviation from the median is represented by the color saturation. Gray indicates missing data. The dendrogram of samples showed that AML patients were classified according to the relative levels of protein or peptide masses as identified by SELDI-TOF in two major clusters, cluster 1 (n ¼ 19) and cluster 2 (n ¼ 18).
Using a threshold value of 73 (calculated with receiver operating characteristic curves), we were able to correctly identify 68% of patients who died (patients with expression levels greater than 73) and 73.3% of patients who survived (patients with expression levels lower than 73), with a specificity of 69 and 74%, respectively. Among normal karyotypes, the median intensity levels of the marker were also different between deceased (193±44.07; range 3.6-395) and surviving patients (22.1 ± 33.24; range 0.5-397), with a highly discriminative P-value (P ¼ 0.007) (Figure 4b ). To further evaluate the correlation of the 10 800-Da marker with survival and to eliminate a bias due to patient selection in the first cohort, we performed an independent SELDI-TOF analysis of a second cohort of patients selected from a different university hospital. Because the results of the first set of patients suggested that this marker was very efficient for survival prediction among AML patients with normal cytogenetics, we selected normal cytogenetic AML patients (NC-AML). In this group, median values for the 10 800-Da marker were 82.0 ± 33 (31.6-280) in deceased patients and 19.4±24.1 (1.19-71.7) in surviving patients (P ¼ 0.01). Using receiver operating characteristic curve analysis, we were able to identify a threshold that predicts death with 85% sensitivity and 72% specificity. Moreover, clustering of patients based on their proteomic profile identified two clusters with significantly different level of 10 800 Da marker (Figure 5a ), and significantly different OS (P ¼ 0.03) and event-free survival (P ¼ 0.03) (Figure 5b ).
S100A8 is the 10 800-Da marker
To identify this 10 800-Da marker, we selected three samples from patients harboring the highest values of this marker. When analyzing peptide mass fingerprints of the first sample, 12 of the observed peaks were attributed to protein S100A8 (also designated MRP8 or calgranulin A). Among these 12 peptides, the amino-acid sequence was obtained for 6 by subsequent fragmentation with very high Mascot scores (at least 47), confirming the identification of this protein. The cumulative length of all 10 peptides encompassed 40.4% of the total aminoacid sequence of S100A8. The same protein purification combined with nanoLC-MS/MS identification was performed on the two other samples and unambiguously identified the S100A8 protein each time. We investigated a few more candidate markers that were also statistically significant, but we failed to validate another prognostic marker.
Source of S100A8 signal
As S100A8 is the major cytosolic component of granulocytes, we investigated the possibility that normal cells contaminated the samples, thus affecting the measured S100A8 levels. For samples originating from peripheral blood (n ¼ 7), we analyzed the correlation between polynuclear cells (PN), monocytes and blast cells with S100A8 levels. The respective P-values were 0.59, 0.21 and 0.10, demonstrating that S100A8 levels did not correlate with PNs or monocyte counts in our study, but that there was a trend between S100A8 MS levels and blast cell counts. For the samples originating from bone marrow, we analyzed the proportion of PNs and monocytes in the initial bone marrow sample before Ficoll separation. The median proportions of PNs, monocytes and blast cells were 4.1% (0-18.5%), 1% (0-34%) and 70% (50-97%), respectively. Taking into account that Ficoll eliminates more than 90% of PNs, the final proportion of PNs in the samples reaches 1.85%, at best. Within monocytes, S100A8 probably represents no more than 5% of cytosolic protein and its expression is about 40-fold lower than in granulocytes (Supplementary Figure 1) . Therefore, taking into account the median monocyte proportion in our S100A8 predicts survival in AML E Nicolas et al samples, the signal originating from monocytes represents a potential S100A8 contamination of o0.5%.
Western blot analysis of S100A8 expression in AML patients
To validate the results obtained by MS peptide sequencing, we performed a western blot analysis of cell lysates obtained from 12 patients from the first set who expressed high (4100) or low (o100) MS levels of the 10 800-Da marker. Figure 6a shows that high MS levels (4100) correlated with a significant western blot expression (r ¼ 0.85) except for one patient (MS intensity 194). Patients who were negative for the marker by MS (relative intensity o10) were also negative by western blot (r ¼ 0.81). However, two patients displayed a western blot expression stronger than expected from their MS levels (26 and 22) . Among 
S100A8 predicts survival in AML
E Nicolas et al patients with protein expression levels detectable by a western blot analysis (n ¼ 7), five were deceased, whereas only two of the patients without levels detectable by western blot analysis (n ¼ 5) were deceased, giving a sensitivity and specificity for death prediction of 70 and 75%, respectively. However, P-value was not significant and just indicated a trend probably due to the too small number of samples analyzed. Interestingly, we found S100A8 protein expression in normal human bone marrow. Purification of CD34( þ ) cells showed that this expression was restricted to the CD34(À) fraction of bone marrow, belonging mainly to the more mature granulocyte (Figure 6b ).
Discussion
There is expanding evidence that proteomic approaches could be beneficial in deciphering the molecular heterogeneity of AML and in improving the prognostic stratification of patients.
In this context, we performed an MS-based proteomic study of leukemic cells that were obtained from de novo AML patients at the time of diagnosis. First, we showed that patients could be clustered based on their protein profiles into two different clusters of significantly different prognostics. Second, we showed that proteomics could improve cytogenetic classifications. A combination of proteomics and cytogenetics allowed the formation of a new stratification that highly correlated with the outcome. In intermediate and unfavorable cytogenetic groups, proteomic profiles could identify two subsets of patients with a significantly increased probability of survival.
One could be skeptical that AML could be simply separated into two groups of bad and good prognosis because genetic studies have shown that AML is a heterogeneous disease. However, correlations between gene mutations and survival have shown that patients with molecular markers of good prognosis, including NPM1 mutations, wild-type WT1, FLT3-ITD negative, core binding factor leukemia, CEBPA mutations and PML-RARA, represent about 45% of AMLs. The remaining leukemias (about 55% of AMLs) include patients with adverse and intermediate prognosis. Similarly, in normal karyotype AML, patients without FLT3-ITD, TK mutations or MLL-PTD represented almost 50% of AMLs and have a prognosis that is significantly more different than that of patients harboring these mutations. 19 Therefore, we think that our proteomic classification reflects the separation into two subgroups of approximately similar size but different prognostics. Further studies on the correlation between molecular status and proteomics could further improve this issue. Previous studies have already shown that the heterogeneity of AML correlates with significant variations in proteins. Cytological FAB subgroups or certain cytogenetic subgroups displayed specific variations of some proteins, and the predictive values of protein profiles have been underscored in acute lymphoblastic leukemia. In AML, the prognostic interest of proteomic approaches was notably demonstrated in a study by Kornblau et al. 17 The authors investigated 51 preselected proteins, including 21 phospho-proteins important for apoptosis, cell cycle and signal transduction, using a reverse phase protein array, and showed that seven protein signature groups correlated with relapse and overall survival. Our study provides additional proof of the predictive value of proteomics using a different strategy based on the global evaluation of the protein signature of leukemic cells. Even though our strategy was impeded by the absence of direct protein identification, this 'blind mining' provides, in our opinion, a more realistic picture of the steady state of leukemic cells. In fact, patient partitioning is not based on the expression of proteins known as major actors of oncogenesis, but on the whole set of detected proteins. Therefore, thanks to this global approach, new proteins or pathways that could affect patients' prognosis may be more likely isolated.
Among the discriminative markers of survival, we identified a 10 800-Da marker that could predict poor prognosis with sensitivity and specificity close to 70%, rising up to 85% in a second independent set of patients. This marker was identified as the S100A8 protein (also designated calgranulin A or MRP8), a protein only expressed in mature granulocytes. Expression levels based on western blot analysis correlated with the MS data in a high proportion of the samples and confirmed that S100A8 is mainly expressed in AML patients with the worst prognosis with 75% specificity. S100A8 belongs to the S100 protein family, which includes 23 different members characterized by two calcium-binding EF hands.
20 S100 proteins are involved in a variety of cellular processes, such as cell cycle regulation, cell growth, cell differentiation and motility. Initially described in mature granulocytes, S100A8 represents the major cytosolic protein of granulocytes and, therefore, is considered to be a maturation marker that is not expressed in normal immature myelocytes and myeloblasts. 21 It is important to note that we demonstrated that levels of PNs and monocytes in the initial samples were not a significant contaminating source of S100A8. Moreover, we confirmed that in normal bone marrow, S100A8 expression is restricted to mature granulocytes because CD34 ( þ ) cells did not express significant levels of S100A8 compared with CD 34(À) cells.
Variations of S100A8 transcripts have been reported in AMLs and correlate with the FAB subtype or with the differentiation of AML. S100A8 transcripts have also been described within a pattern of genes associated with good prognosis AML. Concerning the S100A8 protein, Cui and colleagues 10 have described the use of S100A8 to mark AML differentiation and differentiate AML from acute lymphoblastic leukemia, but to our knowledge, the potential role of S100A8 in AML pathogenesis has never been published. Hence, our results raised two questions: (i) does the S100A8 protein dosage directly influence leukemia progression or only reflect leukemia status?, and (ii) what mechanisms lead to the overexpression of S100A8 in leukemic cells? Genomic rearrangements at chromosomal region 1q21, at which most of the S100 genes are clustered, are frequently observed in human tumors, suggesting a particular link between S100 proteins and cancer. Recently, a concentration-dependent role for soluble S100A8 protein in balancing tumor cell growth and apoptosis was described. 22 The S100A8 protein promoted cell growth via the receptor for advanced glycation end products in tumor cell lines, including murine B-cell leukemia (BJAB) and human T-cell leukemia (Jurkat) lines. Interestingly, the receptor for advanced glycation end products and for advanced glycation end products are involved in leukemic cell proliferation. 23 Advanced glycation end products cause the receptor for advanced glycation end products-dependent activation of MAP kinase, PI3K and JAK/STAT pathways, which are associated with cellular proliferation of HEL leukemia cell line. Moreover, a significant level of expression of the receptor for advanced glycation end products was shown in AML, with statistically more frequent expression in the less lineage-restricted subgroups of AML (according to FAB classification).
24 S100 proteins can also interact with heparin sulfate and proteoglycan. 25 These glycosaminoglycans are expressed in the extracellular matrix of bone marrow, where they could have a regulatory role in hematopoiesis. Hence, S100A8 may also impact normal hematopoiesis, therefore providing another explanation for its correlation with AML prognosis.
Finally, CEBPA has been reported as an enhancer of S100A8 gene activity during granulocyte differentiation. 26 Contrarily, in CEBPA-mutated AML, the N-terminal mutation leading to formation of the truncated 30-kDa isoform originating from an internal ATG site acts as a dominant-negative inhibitor of CEBPA, inhibiting thereby the trans-activation of granulocyte target genes, leading to a blockage of granulocytic differentiation. Thus, we could reasonably hypothesize that wild-type CEBPA patients could display significantly different levels of S100A8 protein compared with patients with mutated CEBPA, thus arguing for the prognostic interest of an S100A8 assay for AML at the time of diagnosis.
In conclusion, our study shows that proteomic profiling of leukemic cells produces an accurate prognostic classification of AML patients, independent of their cytogenetic status. Particularly, proteomic analysis provides a helpful stratification of AML patients with a normal karyotype. Moreover, we show that patients expressing high levels of S100A8 protein, a granulocyte maturation marker, displayed the worst prognosis, suggesting that S100A8 expression by leukemic cells predicts poor survival.
